



Published in final edited form as:

ACS Infect Dis. 2020 March 13; 6(3): 503–514. doi:10.1021/acsinfecdis.9b00425.

Non-anticoagulant Heparin as a Pre-exposure Prophylaxis Prevents Lyme Disease Infection

Yi-Pin Lin,

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States; Department of Biomedical Sciences, State University of New York at Albany, Albany, New York 12222, United States

Yanlei Yu,

Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States

Ashley L. Marcinkiewicz,

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States

Patricia Lederman,

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States

Thomas M. Hart,

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States; Department of Biological Science, State University of New York at Albany, Albany, New York 12222, United States

Fuming Zhang,

Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States

Robert J. Linhardt

Corresponding Authors: Yi-Pin.Lin@health.ny.gov, linhar@rpi.edu.

Author Contributions

Conceptualization: Y.-P.L., F.Z., and R.J.L. Data curation: Y.-P.L., Y.Y., A.L.M., P.L., and T.M.H. Formal analysis: Y.-P.L., Y.Y., A.L.M., F.Z., and R.J.L. Funding acquisition: Y.-P.L., F.Z., and R.J.L. Investigation: Y.-P.L., Y.Y., A.L.M., P.L., T.M.H., F.Z., and R.J.L. Methodology: Y.-P.L., Y.Y., A.L.M., P.L., T.M.H., F.Z., and R.J.L. Project administration: Y.-P.L. and R.J.L. Resources: Y.-P.L., F.Z., and R.J.L.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsinfecdis.9b00425>.

Experimental timeline of NACH inoculation and tick infection in mice (Figure S1); replete ticks acquiring blood from NACH- or PBS-treated mice displaying similar weight and spirochete burdens (Figure S2); spirochetes being undetectable at 56 days post-tick feeding of NACH-treated mice (Figure S3); strains used in this study (Table S1); the generation time of PBS- and NACH-treated *B. burgdorferi* strains used in this study (Table S2); primers used in this study (Table S3) (PDF)

The authors declare no competing financial interest.


Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acsinfecdis.9b00425>

Department of Chemical and Biological Engineering, Department of Chemistry and Chemical Biology, and Departments of Biology and Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180, United States

Abstract

Lyme disease (LD) is caused by the spirochete *Borrelia burgdorferi* sensu lato (*Bbsl*). After transmission to humans by ticks, *Bbsl* spreads to multiple organs, leading to arthritis, carditis, and neuroborreliosis. No effective prophylaxis against human LD prior to tick exposure is currently available. Thus, a pre-exposure prophylaxis (PrEP) against LD is needed. The establishment of LD bacteria at diverse sites is dictated partly by the binding of *Bbsl* to proteoglycans (PGs) and glycosaminoglycans (GAGs) in tissues. The drug heparin is structurally similar to these GAGs and inhibits *Bbsl* attachment to PGs, GAGs, cells, and tissues, suggesting its potential to prevent LD. However, the anticoagulant activity of heparin often results in hemorrhage, hampering the development of this compound as LD PrEP. We have previously synthesized a non-anticoagulant version of heparin (NACH), which was verified for safety in mice and humans. Here, we showed that NACH blocks *Bbsl* attachment to PGs, GAGs, and mammalian cells. We also found that treating mice with NACH prior to the exposure of ticks carrying *Bbsl* followed by continuous administration of this compound prevents tissue colonization by *Bbsl*. Furthermore, NACH-treated mice develop greater levels of IgG and IgM against *Bbsl* at early stages of infection, suggesting that the upregulation of antibody immune responses may be one of the mechanisms for NACH-mediated LD prevention. This is one of the first studies examining the ability of a heparin-based compound to prevent LD prior to tick exposure. The information presented might also be extended to prevent other infectious diseases agents.

Graphical Abstract



Keywords

Lyme disease; *Borrelia*; heparin; NACH; pre-exposure prophylaxis

Transmitted by *Ixodes* ticks, Lyme disease is the most common vector-borne disease in the northern hemisphere.^{1,2} This disease is caused by multiple species of the spirochete *Borrelia burgdorferi* sensu lato. In North America, the majority of human Lyme disease cases is caused by one species of these spirochetes, *B. burgdorferi* sensu stricto (*B. burgdorferi*),³ whereas another species, *B. mayonii*, was recently identified to also cause human Lyme disease in the U.S.⁴ A 2018 CDC study found that U.S. tickborne disease cases doubled from 2004 to 2016, with Lyme disease accounting for 82% of all reports.⁵ Acute illness is commonly treated with antibiotics, but prolonged disease manifestations cost the U.S. health

care system close to \$1.3 billion a year (approximately \$3000 per patient on average).⁶ However, no effective Lyme disease prevention used prior to exposure to ticks is currently available.⁷ Upon the tick bite, Lyme borreliae establish an infection in the skin at the bite site and disseminate through the bloodstream to distal tissues and organs, leading to manifestations including arthritis, carditis, and neuroborreliosis.^{3,8} Such clinical observations support that spirochete attachment to host tissues is a requirement for the development of these manifestations.^{9,10}

Vertebrate hosts generate multiple receptors on the cell surface that are exploited by microbes including Lyme borreliae to facilitate its tissue colonization.^{9,11} One such receptor type is a proteoglycan (e.g., decorin and biglycan), which is composed of a core protein and covalently linked glycan chains, as known as glycosaminoglycans (GAGs).^{12–14} Lyme borreliae less efficiently colonize the tissues of mice defective in producing decorin or biglycan.^{15,16} These spirochetes were also documented to bind to these proteoglycans and several GAGs, including heparan sulfate and dermatan sulfate,^{17–20} and the incubation of these molecules with Lyme borreliae inhibits spirochete attachment to the cells.^{17,20} These results suggest that a spirochete's ability to bind to a proteoglycan or GAG mediates its attachment to host cells and tissues. Furthermore, *intravenous* inoculation of *B. burgdorferi* in conjunction with heparin, a GAG analog, reduces the vascular interaction of spirochetes.^{21,22} This result supports the use of heparin to prevent hematogenous dissemination of Lyme borreliae.

In fact, heparin has been examined as an antimicrobial therapeutic, since it is capable of modulating host immune responses against pathogens.²³ However, heparin has long been used as an anticoagulant to prevent clot formation; thus, this compound often triggers side effects such as thrombocytopenia and bleeding.^{24,25} Additionally, the structure of unfractionated heparin is heterogeneous, and it has many chains, which appear to be associated with this heparin's short half-life in humans (<2 h).²⁶ These properties increase the complexity of using heparin to prevent microbial infection. A low molecular weight fraction of heparin (<8000 Da) has a prolonged half-life.^{27–29} We and others have further modified the structure of low molecular weight heparin to eliminate its anticoagulant activity.^{29,30} This non-anticoagulant version of low molecular weight heparin (NACH) demonstrates no toxicity in mammalian hosts and has been used in humans for clinical trials.^{31–33} The improved pharmacology and safety of NACH raise the possibility of testing the ability of this compound to prevent Lyme disease infection.

In this study, we synthesized NACH, gave it to mice prior to exposure to ticks carrying *B. burgdorferi*, and examined the ability of NACH to prevent Lyme disease infection. We also investigated the mechanisms by which NACH blocked the infection onset and evaluated the possibility of using NACH as a pre-exposure prophylaxis (PrEP) for Lyme disease.

RESULTS

NACH bound to low passage Lyme borreliae strains and prevented these spirochetes from attaching to proteoglycans and GAGs.

Commercially available porcine intestinal heparin was treated with nitrous acid for depolymerization, resulting in the low molecular weight heparin, dalteparin (Figure 1A). This dalteparin was then oxidized with sodium periodate followed by NaBH₄ reduction as described in our previous work (Figure 1A).^{29,30} The resulting product, NACH, was verified for its purity and low anticoagulant activity described in our recent study.²⁹ We next incubated the resulting NACH products or BSA (negative control) with different low passage and infectious Lyme borreliae species or strains, including *B. burgdorferi* strains B31-A3 and 297 (representing two distinct genotypes associated with human infection),³⁴ *B. afzelii* strains CB43 and VS461-JL, and *B. garinii* strains ZQ1 and PBr. A high passage, noninfectious, and nonadherent *B. burgdorferi* strain B314 was also included as a negative control (Table S1).^{35,36} The resulting spirochetes were added to the NACH-coated microtiter plate wells for the determination of spirochete attachment. Less than ten percent of these Lyme borreliae strains bound to BSA as expected (Figure 1B). While the negative control strain B314 bound to NACH at levels no different from that to BSA, more than 15% of other low passaged strains was immobilized by NACH at greater levels than that by BSA (Figure 1B). These results indicate the invariable ability of spirochete strains and species to attach to NACH.

NACH is an analog of heparin, which is structurally similar to the GAG component of proteoglycans binding Lyme borreliae. This raises the possibility that NACH is capable of inhibiting spirochetes binding to these proteoglycans and GAGs. Thus, we mixed NACH or PBS (negative control) with the above-mentioned Lyme borreliae strains and added the mixture into the microtiter plate wells immobilized with different proteoglycans and GAGs. These ligands included decorin, biglycan, heparan sulfate, and dermatan sulfate, and BSA was included as the control. As expected, the nonadherent strain B314 binds to these ligands at undetectable levels (lower than 10% binding) (Figure 1C–G). All infectious spirochete strains when treated with PBS bind to decorin, biglycan, heparan sulfate, and dermatan sulfate but not BSA at the levels greater than the strain B314 (Figure 1C–G). However, after being treated with NACH, these strains bind to the above-mentioned proteoglycans or GAGs no better than the strain B314 (Figure 1C–G), demonstrating that NACH has the ability to reduce spirochete attachment to proteoglycans and GAGs.

NACH Inhibited Spirochete Adhesion to Mammalian Cells.

Since proteoglycans and GAGs are located on the surface of mammalian cells, we sought to determine the ability of NACH to block spirochete attachment to these cells. Different Lyme borreliae species or strains were thus incubated with NACH (or BSA, negative control) prior to being added to different mammalian cells types, including C6 glioma, SVEC endothelial, and SW982 joint synovial cells. These cell lines were selected as they were derived from the tissues that Lyme borreliae often colonize during infection. It is not surprising that less than 10% of the high passage and nonadherent strain B314 attaches to these cell types (Figure 2). After treatment with BSA, the infectious *B. burgdorferi*, *B. afzelii*, and *B. garinii* strains all

bound to C6, SVEC, and SW982 cells at levels greater than the strain B314 (Figure 2). In contrast, treating these infectious Lyme borreliae strains with NACH resulted in lower levels of attachment to these cell lines, compared to the treatment of BSA (Figure 2). These findings show that NACH reduces Lyme borreliae attachment to mammalian cells.

NACH Reduced Spirochetes' Ability To Establish Infection in Mammalian Hosts.

We next *intradermally* inoculated Swiss-Webster mice with NACH or PBS (negative control) to determine the ability of this compound to act as a PrEP in preventing Lyme disease infection (Figure S1). This mouse strain was used as it is outbred and thus more closely reflects the genetically variable background in humans. Additionally, this mouse strain has been commonly used as a model for mammalian Lyme disease infection.^{37–39} Although comparable concentrations of chondroitin sulfate and hyaluronic acids were detected in NACH- and PBS-treated mice at 24 h post-inoculation, we observed greater levels of heparan sulfate in the NACH-treated mice (Table 1). This result is in agreement with the fact that heparan sulfate has a similar disaccharide unit to NACH,^{29,30} and it also verifies the bioavailability of NACH through this inoculation route. Twenty four hours after administration, the *I. scapularis* nymphs carrying *B. burgdorferi* strains B31-A3 or 297 were allowed to feed on these mice until repletion (Figure S1). These mice were continuously inoculated daily in the same fashion with NACH until they were euthanized (Figure S1). The replete nymphs were weighed to evaluate their feeding quality, and the DNA extracted from the nymphs and tissues at different time points was collected to determine their bacterial burdens.

We found that the replete ticks feeding on NACH-inoculated mice do not weigh differently than the ticks feeding on PBS-administrated mice. This trend applied to the ticks carrying either B31-A3 or 297 strains (Figure S2A). These results indicate that NACH does not interfere with tick feeding. Compared to flat nymphs, the spirochete burdens in fully engorged nymphs increased approximately 10-fold, as reported previously (Figure S2B).^{40,41} However, no differences in bacterial burdens were found in the strains B31- or 297-carrying nymphs feeding on NACH- or PBS-inoculated mice (Figure S2B). These observations show that NACH does not eliminate the spirochetes in ticks during feeding.

We also found that no spirochetes are detectable at the biting sites in the skin of PBS-inoculated and uninfected mice at 7 days post-tick feeding, as expected (Figure 3A). At this time point, the bacterial burdens of the PBS- or NACH-administrated mice fed on by ticks carrying the *B. burgdorferi* strain B31-A3 were greater than that in uninfected mice (Figure 3A). Between those infected mice, the spirochete loads were lower in NACH-treated individuals, compared to PBS-treated animals (Figure 3A). These results demonstrate the ability of NACH to reduce the infection establishment by Lyme borreliae in mammalian hosts. We were unable to detect the spirochetes at the heart, joints, ears, and bladder of PBS-inoculated and uninfected mice at 7 days post-tick feeding (Figure 3B–F). Similarly, the bacterial loads of either NACH- or PBS-treated animals were undetectable in these tissues, suggesting that *B. burgdorferi* has not disseminated to these distal tissues at 7 days post-tick feeding (Figure 3B–F).

NACH Facilitated *B. burgdorferi* Clearance at Tick Biting Sites and in the Bloodstream To Prevent Spirochete Dissemination to Distal Tissues.

We sought to determine the burdens of the *B. burgdorferi* strain B31-A3 in tick biting sites at 14 days post-tick feeding. PBS-inoculated and uninfected mice did not develop detectable spirochete burdens at the biting site of the skin (Figure 4A). Although we were able to detect bacteria at this tissue and this time point from the PBS-inoculated and the strain B31-A3-infected mice, no spirochetes were detected at the biting site of the skin from NACH-inoculated mice (Figure 4A). Similarly, we also measured the spirochete burdens in tick biting sites of the skin at 56 days post-tick feeding and did not detect *B. burgdorferi* in this tissue of NACH-treated mice (Figure S3A). These results suggest that NACH inoculation promotes spirochete elimination at the infection-initiation site. Additionally, we were incapable of detecting spirochetes in the biting site of the skin from NACH-administrated mice at 56 days after these mice were fed on by ticks carrying the *B. burgdorferi* strain 297 (Figure S3A). This result suggests that such a NACH-mediated spirochete eradication at the tick biting sites can be extended to other Lyme borreliæ strains.

We also determined the burdens of the *B. burgdorferi* strain B31-A3 in the heart, joints, ears, and bladder at 14 days post-tick feeding. While spirochetes were undetectable in these tissues of PBS-inoculated and uninfected mice, approximately 10^3 of the strain B31-A3 were found to colonize at the heart, joints, ears, and bladder of mice administrated with PBS and fed on by ticks carrying this spirochete strain (Figure 4B–F). Interestingly, no bacteria were detected at these distal tissues of NACH-administrated mice followed by being infected using ticks carrying the strain B31-A3 (Figure 4B–F). Similar trends of undetectable colonization at the joints, heart, ears, and bladder were found in NACH-treated mice at 56 days post-feeding (Figure S3B–F). These observations suggest that NACH-treatment prevents spirochete dissemination to distal tissues. Further, we did not observe the colonization of any spirochetes at these tissues of NACH-treated mice when mice were infected with *B. burgdorferi* strain 297 (Figure S3B–F). These results clearly point out the ability of NACH to prevent multiple Lyme borreliæ strains' dissemination.

The fact that Lyme borreliæ dissemination requires the ability to survive in the bloodstream raises the possibility that NACH may facilitate hematogenous clearance of spirochetes, preventing dissemination. Thus, we determined the spirochete burdens in the mouse bloodstream at different time points after tick feeding. The *B. burgdorferi* strain B31-A3 survived at indistinguishable levels in the bloodstream of PBS- or NACH-treated mice at 4 days post-tick feeding (Figure 5A). However, compared to PBS-treated mice where the strain B31-A3 survival was close to being uninfluenced, the burdens of this strain in NACH-treated mice were reduced at 7 days and undetectable at 10 days post-feeding (Figure 5B,C). Fourteen days after tick feeding, we were unable to detect the spirochetes in the bloodstream of either PBS-inoculated or NACH-treated mice (Figure 5D). This result is in agreement with the adaptive immune clearance of Lyme borreliæ in the bloodstream at this time point.^{42,43} Taken together, these findings indicate faster kinetics of the hematogenous clearance of *B. burgdorferi* in NACH-treated mice.

NACH-Treated Mice Developed More Robust Early Antibody Immune Responses against Spirochetes after Lyme Disease Infection.

Our finding that *B. burgdorferi* is more rapidly eliminated in NACH-treated mice than in PBS-inoculated mice leads to the possibility that NACH facilitates spirochete clearance. However, we found that the number of motile *B. burgdorferi* strains B31-A3 or 297 does not decrease after the treatment of NACH, similar to these strains treated with PBS (data not shown). Additionally, both strains treated with NACH had doubling times (generation time) no different than those treated with PBS (Table S2). These results indicate that NACH does not directly kill Lyme borreliae. As antibody responses play a key role to clear Lyme borreliae during infection, we next sought to examine whether such immune responses are modulated by NACH. Mice were given NACH (or PBS) 1 day prior to the exposure to ticks carrying the *B. burgdorferi* strain B31-A3 and were continuously administered NACH daily after infection. Blood was collected at different time points to examine for the levels of IgG and IgM against spirochetes. As expected, IgM titers in infected mice treated with either NACH or PBS were no greater than that in uninfected mice at 4 days post-tick feeding (Figure 6A). The mice fed on by nymphs under either treatment developed greater titers of IgM than the uninfected mice at 7, 10, and 14 days post-tick feeding, indicating that both mice were infected by *B. burgdorferi* (Figure 6B–D). However, while the IgM levels of PBS-treated and *B. burgdorferi*-infected mice remained higher than that in uninfected mice at 21 and 56 days postfeeding, antibody levels of infected mice treated with NACH were no different from that in uninfected mice (Figure 6E,F). These results are consistent with the fact that spirochetes are cleared from tissues and bloodstream at those time points in NACH-treated mice (Figures 4, 5, and S3). Interestingly, after infection, NACH-treated mice developed greater IgM titers than PBS-inoculated mice at 7 days post-tick feeding. This result suggests that NACH triggers efficient IgM responses at early stages of infection (Figure 6B).

Similarly, all the mouse groups did not generate detectable titers of IgG at 4 days post-feeding (Figure 6G). The infected mice under either NACH or PBS treatment developed greater IgG titers than the uninfected mice at 10, 14, and 21 days postfeeding (Figure 6I–K). The IgG titers of NACH-treated, *B. burgdorferi*-infected mice were lower than that in PBS-inoculated, spirochete-infected mice at 21 days post-tick feeding and undetectable at 56 days post-tick feeding (Figure 6K,L). These data are in agreement with the elimination of *B. burgdorferi* in NACH-treated mice at these time points. Similar to IgM, the IgG titers in infected mice treated with NACH were greater than that in the infected mice treated with PBS at 7 days post-tick feeding (Figure 6H). These results suggest the ability of NACH to induce early IgG responses. Taken together, these observations indicate that NACH administration triggers robust antibody immune responses against spirochetes early during Lyme disease infection.

DISCUSSION

Lyme borreliae bind to GAGs and proteoglycans,^{17–20} and such binding activity facilitates spirochete attachment to mammalian cells/tissues under static^{35,44–47} or shear stressed conditions.^{20–22,48–50} Among those ligands, decorin, biglycan, and dermatan sulfate were

reported to bind to spirochetes, promoting tissue colonization of spirochetes and Lyme disease-associated manifestations.^{15,16,51–53} We found that Lyme borreliae species and strains display a universal capability of binding to NACH, an analog of GAGs. We also demonstrated that NACH-treated spirochetes display reduced binding ability to different purified GAGs and proteoglycans, compared to untreated bacteria. Our findings raise a possibility that NACH blocks spirochete binding to GAGs and proteoglycans, inhibiting the colonization and disease manifestations caused by Lyme borreliae infection. This notion is supported by our observation of less efficient spirochete colonization at inoculation sites and distal tissues in the mice treated with NACH, compared to negative control mice. Further, such GAG- and proteoglycan-binding activities of Lyme borreliae have been attributed to several GAG- and/or proteoglycan-binding proteins on the surface of spirochetes.^{44,45,51,54–56} Additionally, spirochetes deficient of some of these GAG- and proteoglycan-binding outer surface proteins less efficiently colonize at tissue and trigger manifestations than the parental wild-type strain.^{47,52,53} Thus, our finding of NACH's efficacy to prevent spirochete colonization leads to an intriguing question: Does NACH target these Lyme borreliae outer surface proteins to inhibit dissemination? Such a question warrants further investigations.

Vertebrate animals develop innate immune responses to eradicate Lyme borreliae immediately after spirochetes invade these hosts, which serve as a bottleneck prior to the infection establishment.^{57–61} Adaptive immune responses are activated later, which control spirochete burdens, resulting in reduced and persistent colonization at the tissues.^{62–65} Specifically, the levels of antibodies against Lyme borreliae or their outer surface antigens in sera have been correlated with the spirochete loads at the tissues, supporting the role of B cell responses in mediating Lyme borreliae clearance.^{66,67} Therefore, a more robust antibody production at the earlier infection onset would be expected to facilitate a more efficient clearance of spirochetes. Such effective eradication could then prevent spirochete dissemination to and colonization at distal tissues. In fact, we found that mice inoculated with NACH followed by being infected with Lyme borreliae develop greater levels of IgG and IgM against spirochetes at early stages of infection. These results are supported by the previous findings showing that low molecular weight heparin is capable of modulating host immune responses, resulting in more efficient elimination of pathogenic bacteria by mammalian hosts.²³ Additionally, the kinetics of NACH-mediated robust antibody production match the onset of spirochete eradications at tick biting sites and in the bloodstream. This coincidence suggests that high levels of antibody generation against spirochetes at early stages of infection are likely one of the mechanisms for NACH to prevent Lyme disease infection.

In this study, we could not detect spirochetes at 56 days post-tick feeding when NACH was given to the mice prior to the exposure to ticks carrying Lyme borreliae and introduced daily after infection. Six different tissues previously shown to be colonized by Lyme borreliae after tick feeding were included. These results do not rule out the possibility that spirochetes remain and colonize other untested tissues. However, that scenario is unlikely because of the decreasing numbers of antibodies against spirochetes from 14 to 21 days after tick feeding and the seronegative results at 56 days post-tick feeding in NACH-treated mice. Furthermore, antibiotics are available as prophylaxis to prevent Lyme disease immediately after tick

exposure.⁶⁸ However, the fact that many people do not notice a tick bite addresses the need of the prevention prior to tick infection. The only currently developed PrEP is a monoclonal antibody, which blocks tick-to-host transmission of Lyme borreliae by targeting a spirochete outer surface protein, OspA.⁶⁹ Unlike that prophylaxis, NACH targets GAG/proteoglycan-binding activity and upregulates antibody immune responses, which are not Lyme borreliae-specific. Thus, NACH may be potentially extended to prevent the infection caused by other pathogens.

CONCLUSION

Our results highlight the potential of using NACH as a PrEP to prevent Lyme disease infection, but it is noted that the intradermal route and a comparatively short half-life of the NACH regimen used in this study (~12 h) may not be ideal for PrEP development.³³ Many excipients have been used to formulate heparin to enhance the oral bioavailability and increase the half-life.^{70–74} These findings shed light on the further development of NACH as a more suitable compound for human use as Lyme disease PrEP. Additionally, the oral administration of prevention by targeting the reservoir animals has been examined as a strategy to reduce the risk of exposure to Lyme borreliae.^{75–78} Thus, our findings also provide a possibility to use NACH as a bait for reservoir hosts in Lyme disease prevention through the formulation to enhance oral bioavailability and half-life. In this proof-of-concept study, we examined the possibility of using NACH prior to tickborne Lyme borreliae transmission to prevent spirochete colonization. We also investigated the potential mechanisms that drive NACH-mediated protection against Lyme disease. The results derived from this study will provide the foundation to ultimately enable us to reduce the burdens of human Lyme disease.

METHODS

Ethics Statement.

All mouse experiments were performed in strict accordance with all provisions of the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the PHS Policy on Humane Care and Use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee of Wadsworth Center, New York State Department of Health (protocol Docket Number 19-451). All efforts were made to minimize animal suffering.

Mouse, Ticks, Bacterial Strains, Antisera, and Enzymes.

Swiss-Webster mice were purchased from Taconic (Hudson, NY). *Ixodes scapularis* tick larvae were obtained from BEI Resources (Manassas, VA). *B. burgdorferi*-infected nymphs were generated as described in Generation of Nymphal Ticks Carrying *B. burgdorferi*. All *B. burgdorferi*, *B. afzelii*, and *B. garinii* strains used in this study were grown in BSK-II complete medium (Table S1). To generate the antisera against different Lyme borreliae species, *B. burgdorferi* strain B31-A3, *B. afzelii* strain VS461-JL, or *B. garinii* strain ZQ1 was *intra-dermally* introduced into mice (10^6 bacteria per mouse). At 21 days post-infection, an ear biopsy (one biopsy per mouse) was collected to determine the infectivity of the

particular strain used to infect that mouse using quantitative PCR (qPCR; see Quantitative PCR and the previous description⁵³). Sera were collected from the qPCR-positive mice, and its seropositivity was verified for the particular strain used to infect that mouse using ELISA as described previously.⁷⁹ Chondroitin lyase ABC from *Proteus vulgaris* was expressed in our laboratory. Recombinant *Flavobacterium* heparin lyases I, II, and III were expressed in our laboratory previously.⁸⁰

Production, Purification, and Verification of NACH.

NACH was synthesized from the low molecular weight heparin, dalteparin, through nitrous acid depolymerization of porcine intestinal heparin, followed by periodate oxidation as described in our previous work.^{29,30} Briefly, one gram of dalteparin (>95% purity) in aqueous solution (8.75 mL, pH 5.0) was added to a freshly prepared 140 mM NaIO₄ solution (25 mL, pH 5.0) in a single portion with stirring. The oxidation was carried out at 4 °C for 24 h in the dark before the solution was desalted using 3 kDa cutoff spin columns. NaBH₄ (50 mg) was added to the reaction to reduce the generated aldehydes. NACH was precipitated by adding ethanol to 80% (v/v). The final NACH product (>95% purity) was obtained by desalting and lyophilization. The structure of NACH was confirmed by NMR with the average MWs (~3870 Da) measured by gel permeation chromatography (GPC). A very low anticoagulant activity (6 U/mg as anti-Xa potency) of NACH was detected by using a BIOPHEN heparin anti-Xa (2 stages) kit (Aniara Diagnostica, West Chester, OH). GPC and disaccharide analysis confirmed the >95% purity of NACH using USP enoxaparin as a standard.

Determining the Serum Concentration of GAGs Derived from NACH.

Mice were *intradermally* injected with NACH (5 mg per kg of mouse), and sera were collected from these mice at 24 h post-inoculation. The determination of GAG composition in the sera has been described previously.^{81,82} Basically, 20 μ L of sera was loaded onto a spin column (molecular weight cutoff of 3 kDa),⁷⁶ and then, the column was washed with distilled water. The upper solution was mixed with 300 μ L of digestion buffer⁷⁶ and a mixture of GAG lyases, including heparin lyase I, II, and III as well as chondroitin lyase ABC (10 mU for each GAG lyase). After incubation at 37 °C overnight, the reaction mixture was applied to a spin column with a molecular weight cutoff of 3 kDa to terminate the reaction by GAG lyases. After air-drying the flow through, the sample was labeled with 2-aminoacridone (AMAC) by being incubated with 10 μ L of AMAC (0.1 M, Sigma-Aldrich) in DMSO/acetic acid (17/3, V/V, Sigma-Aldrich) at room temperature for 10 min, followed by being mixed with 10 μ L of NaBH₃CN (1 M) at 45 °C for 1 h. The resulting samples were spun down, and the supernatant was collected and stored in a light resistant container at room temperature until analysis via LC-MS/MS.

LC was performed on an Agilent 1200 LC system at 45 °C using an Agilent Poroshell 120 ECC18 (2.7 μ m, 3.0 X 50 mm) column (Agilent Technology, Santa Clara, CA). The mobile phases A (MPA) and B (MPB) were ammonium acetate (50 mM) and methanol, respectively. The gradient used for purification was 5% to 45% MPB/95 to 55% MPA from 0 to 10 min, 45% to 100% MPB/55% to 0% MPA from 10 to 10.2 min, 100% MPB/0% MPA from 10.2 to 14 min, 100% to 5% MPB/0% to 95% MPA from 14 to 22 min. The flow rate

was 300 μL per minute. A triple quadrupole mass spectrometry system equipped with an ESI source (Thermo Fisher Scientific, San Jose, CA) was used as the detector. The online MS analysis was at the multiple reaction monitoring (MRM) mode. The parameters for MS analysis are as follows: negative ionization mode with a spray voltage of 3000 V, a vaporizer temperature of 300 $^{\circ}\text{C}$, and a capillary temperature of 270 $^{\circ}\text{C}$.

Binding of Spirochetes to NACH.

One hundred microliters of NACH or BSA (negative control) at a concentration of 1 mg mL⁻¹ in the coating buffer (0.1 M carbonate/bicarbonate, pH 9.6⁵¹) was added to ELISA microtiter plate wells (ThermoScientific, Pittsburgh, PA). The plates were then incubated for 16 h at 4 $^{\circ}\text{C}$ followed by being blocked using 5% PBS–BSA. Spirochetes suspended in BSK-H medium were added to wells with the immobilized NACH at 1×10^6 spirochetes per well. To enhance spirochete cell contact, the plates were centrifuged at 106g for 5 min and then rocked at room temperature for 1 h. Unbound bacteria were removed by washing with PBS containing 0.2% BSA. To generate the plate wells with bacteria for the purpose of normalization, spirochetes (1×10^6 per well) suspended in the coating buffer were added to the plate wells. Immobilized Lyme borreliae or the spirochetes bound on NACH (or BSA) were fixed using 3% paraformaldehyde followed by 100% chilled methanol. After the plates were air-dried, the antisera against *B. burgdorferi*, *B. afzelii*, or *B. garinii* (1:200 \times) and HRP-conjugated goat antimouse IgG (ThermoFisher; 1:2000 \times) were used as primary and secondary antibodies, respectively. The plates were washed three times with PBST (0.05% Tween 20 in PBS), and 100 μL of tetramethylbenzidine solution (ThermoFisher) was added to each well; the wells were incubated for 5 min. The reaction was stopped by adding 100 μL of 0.5% hydrosulfuric acid to each well. The absorption at 405 nm of each well was obtained by reading the plates at that wavelength using a Tecan Sunrise Microplate reader (Tecan, Morrisville NC). The percent binding of spirochetes was derived from the absorption values of spirochete attachment to each well normalized to the values obtained from the wells immobilized with 1×10^6 of those spirochetes.

Inhibition of Proteoglycan, GAG, and Mammalian Cell Binding with Exogenous NACH.

One hundred microliters of human decorin (gifts from Drs. David Mann and Nancy Ulbrandt), human biglycan (Sigma-Aldrich, St. Louis, MO), heparin sulfate (Sigma-Aldrich), porcine dermatan sulfate (Millipore Billerica, MA), or BSA (negative control) at a concentration of 1 mg mL⁻¹ in the coating buffer was added to ELISA microtiter plate wells. The plates were then incubated for 16 h at 4 $^{\circ}\text{C}$ followed by being blocked using 5% PBS–BSA. For the plate wells cultivated with mammalian cells, C6 rat glioma, SVEC rat endothelial, or SW982 human synovial cells (gifts provided by Dr. John Leong) were added into microtiter plate wells (1×10^5 per well). Spirochetes (1×10^6) were prepared as described in “Binding of Spirochetes to NACH” and incubated for 30 min at room temperature in BSK-H supplemented with 1 mg mL⁻¹ NACH. Spirochetes were then added into these proteoglycans- or GAGs-coated plate wells and incubated at room temperature for 1 h. The percent binding of spirochetes was determined as described earlier.

Determination of Spirochete Killing Activity of NACH *in Vitro*.

We evaluated the viability of NACH-treated spirochetes with a survival assay and growth curve. To determine the spirochetes' viability, 10^6 *B. burgdorferi* strains B31-A3 or 297 in BSK-II complete were treated with PBS buffer or 100 μg of NACH in this buffer and incubated at 33 °C in triplicate. The motility of the bacteria as determined as viable cells was observed initially and again after 24 h using dark field microscopy by evaluating four fields of view.⁸³ The percentage of motile spirochetes was determined as described.^{40,83} These spirochetes were then seeded in BSK II medium, also in triplicate, to determine the spirochetes' generation time as previously described.⁸⁴

Generation of Nymphal Ticks Carrying *B. burgdorferi*.

The experimental procedure has been described previously.⁴⁰ Basically, four week-old male and female C3 deficient BALB/c mice were infected with 10^5 of the *B. burgdorferi* strain B31-A3 or 297 by intradermal injection (1×10^5 spirochetes per mouse). The plasmid profiles of strain B31-A3 were verified prior to infection as described to ensure no loss of plasmids.^{85–87} The strain 297 was maintained at passages less than ten. The ear punches from those mice were collected and examined in the presence of spirochete DNA at 7 days post-infection using qPCR as described to confirm the infection of these mice.⁴⁰ At 14 days post-infection, the uninfected *I. scapularis* larvae were allowed to feed to repletion on those *B. burgdorferi*-infected mice as described previously.⁴⁰ Approximately 100 to 200 larvae were allowed to feed on each mouse. The engorged larvae were collected and allowed to molt into nymphs in 4 to 6 weeks in a desiccator at room temperature and 95% relative humidity in a room with light–dark control (light to dark, 12:12 h).

NACH Inoculation and *B. burgdorferi* Infection via Ticks.

Four week-old female Swiss-Webster mice were *intradermally* inoculated with NACH in PBS (5 mg per kg of mouse) or PBS (control). The tick infection procedure was described previously.⁴⁰ Basically, at 24 h post-inoculation, ten nymphs were allowed to feed on each mouse until repletion, and replete nymphs were collected for weight measurement. After placing nymphs on those mice, these mice were continuously given NACH or PBS daily in the same fashion. Uninfected and PBS-inoculated mice were included as negative controls. Blood was collected at 4, 7, 10, and 14 days post-tick feeding whereas sera were obtained at 4, 7, 10, 14, 21, and 56 days post-tick feeding. Mice were euthanized at 7, 14, and 56 days after tick feeding, and the feeding sites of the skin, the tibiotarsus and knee joints, heart, ears, and bladder were collected. Animal tissues, blood, and ticks were used to quantitatively evaluate the levels of colonization during infection (see Quantitative PCR) while sera were used to measure the levels of antibodies (see Quantification of Antibody Titers against *B. burgdorferi*).

Quantitative PCR.

DNA was extracted using an EZ-10 Spin Column Blood DNA Mini-Prep Kit (BioBasic, Inc., Markham, Ontario, Canada). The quantity and quality of DNA for each tissue, tick, or blood sample were assessed by measuring the concentration of DNA and the ratio of the UV absorption at 260 to 280 nm using a Nanodrop 1000 UV/vis spectrophotometer

PrEP	pre-exposure prophylaxis
PG	proteoglycan
GAG	glycosaminoglycan
NACH	non-anticoagulant heparin
Bbsl	<i>Borrelia burgdorferi</i> sensu lato
B. burgdorferi	<i>B. burgdorferi</i> sensu stricto
HepSO₄	heparan sulfate
ChonSO₄	chondroitin sulfate
DermSO₄	dermatan sulfate
Bb	<i>B. burgdorferi</i>
Ba	<i>B. arzelii</i>
Bg	<i>B. garinii</i>
dpf	days post-tick feeding
MRM	multiple reaction monitoring
TMB	tetramethylbenzidine
AU	arbitrary unit

REFERENCES

- (1). Brisson D, Drecktrah D, Eggers CH, and Samuels DS (2012) Genetics of *Borrelia burgdorferi*. *Annu. Rev. Genet* 46, 515–36. [PubMed: 22974303]
- (2). Rosa PA, Tilly K, and Stewart PE (2005) The burgeoning molecular genetics of the Lyme disease spirochaete. *Nat. Rev. Microbiol* 3 (2), 129–43. [PubMed: 15685224]
- (3). Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, and Mead PS (2016) Lyme borreliosis. *Nature reviews. Disease primers* 2, 16090.
- (4). Pritt BS, Mead PS, Johnson DKH, Neitzel DF, Respicio-Kingry LB, Davis JP, Schiffman E, Sloan LM, Schriefer ME, Replogle AJ, Paskewitz SM, Ray JA, Bjork J, Steward CR, Deedon A, Lee X, Kingry LC, Miller TK, Feist MA, Theel ES, Patel R, Irish CL, and Petersen JM (2016) Identification of a novel pathogenic *Borrelia* species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. *Lancet Infect. Dis* 16 (5), 556–564. [PubMed: 26856777]
- (5). Rosenberg R, Lindsey NP, Fischer M, Gregory CJ, Hinckley AF, Mead PS, Paz-Bailey G, Waterman SH, Drexler NA, Kersh GJ, Hooks H, Partridge SK, Visser SN, Beard CB, and Petersen LR (2018) Vital Signs: Trends in Reported Vectorborne Disease Cases - United States and Territories, 2004–2016. *MMWR. Morbidity and mortality weekly report* 67 (17), 496–501. [PubMed: 29723166]
- (6). Adrion ER, Aucott J, Lemke KW, and Weiner JP (2015) Health care costs, utilization and patterns of care following Lyme disease. *PLoS One* 10 (2), e0116767. [PubMed: 25650808]
- (7). Gomes-Solecki M, Arnaboldi PM, Backenson PB, Benach JL, Cooper CL, Dattwyler RJ, Diuk-Wasser M, Fikrig E, Hovius JW, Laegreid W, Lundberg U, Marconi RT, Marques AR, Molloy P, Narasimhan S, Pal U, Pedra JHF, Plotkin S, Rock DL, Rosa P, Telford SR, Tsao J, Yang XF, and

- Schutzer SE (2019) Protective Immunity and New Vaccines for Lyme Disease. *Clin. Infect. Dis.*, DOI: 10.1093/cid/ciz872.
- (8). Radolf JD, Caimano MJ, Stevenson B, and Hu LT (2012) Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. *Nat. Rev. Microbiol* 10 (2), 87–99. [PubMed: 22230951]
 - (9). Coburn J, Leong J, and Chaconas G (2013) Illuminating the roles of the *Borrelia burgdorferi* adhesins. *Trends Microbiol* 21 (8), 372–9. [PubMed: 23876218]
 - (10). Hyde JA (2017) *Borrelia burgdorferi* Keeps Moving and Carries on: A Review of Borrelial Dissemination and Invasion. *Front. Immunol* 8, 114. [PubMed: 28270812]
 - (11). Chagnot C, Lustrat A, Astruc T, and Desvaux M (2012) Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components. *Cell. Microbiol* 14 (11), 1687–96. [PubMed: 22882798]
 - (12). Kamhi E, Joo EJ, Dordick JS, and Linhardt RJ (2013) Glycosaminoglycans in infectious disease. *Biological reviews of the Cambridge Philosophical Society* 88 (4), 928–43. [PubMed: 23551941]
 - (13). Lin YP, Li L, Zhang F, and Linhardt RJ (2017) *Borrelia burgdorferi* glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease. *Microbiology* 163 (12), 1759–1766. [PubMed: 29116038]
 - (14). Lin Y-P, Osburne M, Pereira M, Coburn J, and Leong JM (2016) Glycosaminoglycan Binding by the Lyme Disease Spirochete is a Determinant of Tissue Tropism and Disease, 1 ed., p 334, CRC Press.
 - (15). Brown EL, Wooten RM, Johnson BJ, Iozzo RV, Smith A, Dolan MC, Guo BP, Weis JJ, and Hook M (2001) Resistance to Lyme disease in decorin-deficient mice. *J. Clin. Invest* 107 (7), 845–52. [PubMed: 11285303]
 - (16). Cuellar J, Pietikainen A, Glader O, Liljenback H, Soderstrom M, Hurme S, Salo J, and Hytonen J (2019) *Borrelia burgdorferi* Infection in Biglycan Knockout Mice. *J. Infect. Dis* 220 (1), 116–126. [PubMed: 30698707]
 - (17). Leong JM, Wang H, Magoun L, Field JA, Morrissey PE, Robbins D, Tatro JB, Coburn J, and Parveen N (1998) Different classes of proteoglycans contribute to the attachment of *Borrelia burgdorferi* to cultured endothelial and brain cells. *Infect. Immun* 66 (3), 994–9. [PubMed: 9488387]
 - (18). Parveen N, Robbins D, and Leong JM (1999) Strain variation in glycosaminoglycan recognition influences cell-type-specific binding by lyme disease spirochetes. *Infection and immunity* 67 (4), 1743–1749. [PubMed: 10085013]
 - (19). Guo BP, Norris SJ, Rosenberg LC, and Hook M (1995) Adherence of *Borrelia burgdorferi* to the proteoglycan decorin. *Infection and immunity* 63 (9), 3467–72. [PubMed: 7642279]
 - (20). Salo J, Pietikainen A, Soderstrom M, Auvinen K, Salmi M, Ebady R, Moriarty TJ, Viljanen MK, and Hytonen J (2016) Flow-Tolerant Adhesion of a Bacterial Pathogen to Human Endothelial Cells Through Interaction With Biglycan. *J. Infect. Dis* 213 (10), 1623–31. [PubMed: 26740275]
 - (21). Moriarty TJ, Norman MU, Colarusso P, Bankhead T, Kubes P, and Chaconas G (2008) Real-time high resolution 3D imaging of the lyme disease spirochete adhering to and escaping from the vasculature of a living host. *PLoS Pathog.* 4 (6), e1000090. [PubMed: 18566656]
 - (22). Norman MU, Moriarty TJ, Dresser AR, Millen B, Kubes P, and Chaconas G (2008) Molecular mechanisms involved in vascular interactions of the Lyme disease pathogen in a living host. *PLoS Pathog.* 4 (10), e1000169. [PubMed: 18833295]
 - (23). Sharma L, Wu J, Patel V, Sitapara R, Rao NV, Kennedy TP, and Mantell LL (2014) Partially-desulfated heparin improves survival in *Pseudomonas* pneumonia by enhancing bacterial clearance and ameliorating lung injury. *J. Immunotoxicol* 11 (3), 260–7. [PubMed: 24099632]
 - (24). Oduah EI, Linhardt RJ, and Sharfstein ST (2016) Heparin: Past, Present, and Future. *Pharmaceuticals* 9 (3), 38.
 - (25). Hirsh J (1984) Heparin induced bleeding. *Nouv. Rev. Fr. Hematol* 26 (4), 261–266. [PubMed: 6382162]
 - (26). Mohamed S, and Coombe DR (2017) Heparin Mimetics: Their Therapeutic Potential. *Pharmaceuticals* 10 (4), 78.

- (27). Boneu B, Caranobe C, and Sie P (1990) Pharmacokinetics of heparin and low molecular weight heparin. *Baillieres Clin Haematol* 3 (3), 531–44. [PubMed: 2176903]
- (28). Alban S, Welzel D, and Hemker HC (2002) Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH. *Semin. Thromb. Hemostasis* 28 (4), 369–78.
- (29). Ouyang Y, Yu Y, Zhang F, Chen J, Han X, Xia K, Yao Y, Zhang Z, and Linhardt RJ (2019) Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications. *J. Med. Chem* 62 (2), 1067–1073. [PubMed: 30608147]
- (30). Islam T, Butler M, Sikkander SA, Toida T, and Linhardt RJ (2002) Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. *Carbohydr. Res* 337 (21–23), 2239–43. [PubMed: 12433488]
- (31). Mousa SA, Linhardt R, Francis JL, and Amirkhosravi A (2006) Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. *Thromb. Haemostasis* 96 (6), 816–21. [PubMed: 17139378]
- (32). Yu L, Garg HG, Li B, Linhardt RJ, and Hales CA (2010) Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats. *Curr. Cancer Drug Targets* 10 (2), 229–241. [PubMed: 20201787]
- (33). O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, and Ryan DP (2017) Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. *Oncologist* 22 (12), 1429–e139. [PubMed: 29158367]
- (34). Jones KL, McHugh GA, Glickstein LJ, and Steere AC (2009) Analysis of *Borrelia burgdorferi* genotypes in patients with Lyme arthritis: High frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. *Arthritis Rheum.* 60 (7), 2174–82. [PubMed: 19565522]
- (35). Fischer JR, Parveen N, Magoun L, and Leong JM (2003) Decorin-binding proteins A and B confer distinct mammalian cell type-specific attachment by *Borrelia burgdorferi*, the Lyme disease spirochete. *Proc. Natl. Acad. Sci. U. S. A* 100 (12), 7307–12. [PubMed: 12773620]
- (36). Sadziene A, Wilske B, Ferdows MS, and Barbour AG (1993) The cryptic *ospC* gene of *Borrelia burgdorferi* B31 is located on a circular plasmid. *Infect. Immun* 61 (5), 2192–5. [PubMed: 8478109]
- (37). Gilmore RD Jr., Howison RR, Dietrich G, Patton TG, Clifton DR, and Carroll JA (2010) The *bba64* gene of *Borrelia burgdorferi*, the Lyme disease agent, is critical for mammalian infection via tick bite transmission. *Proc. Natl. Acad. Sci. U. S. A* 107 (16), 7515–20. [PubMed: 20368453]
- (38). Hojgaard A, Eisen RJ, and Piesman J (2008) Transmission dynamics of *Borrelia burgdorferi* s.s. during the key third day of feeding by nymphal *Ixodes scapularis* (Acari: Ixodidae). *J. Med. Entomol* 45 (4), 732–6. [PubMed: 18714875]
- (39). Stewart PE, Wang X, Bueschel DM, Clifton DR, Grimm D, Tilly K, Carroll JA, Weis JJ, and Rosa PA (2006) Delineating the requirement for the *Borrelia burgdorferi* virulence factor *OspC* in the mammalian host. *Infection and immunity* 74 (6), 3547–53. [PubMed: 16714587]
- (40). Hart T, Nguyen NTT, Nowak NA, Zhang F, Linhardt RJ, Diuk-Wasser M, Ram S, Kraiczy P, and Lin YP (2018) Polymorphic factor H-binding activity of CspA protects Lyme borreliae from the host complement in feeding ticks to facilitate tick-to-host transmission. *PLoS Pathog.* 14 (5), e1007106. [PubMed: 29813137]
- (41). Kasumba IN, Bestor A, Tilly K, and Rosa PA (2016) Virulence of the Lyme disease spirochete before and after the tick bloodmeal: a quantitative assessment. *Parasites Vectors* 9, 129. [PubMed: 26951688]
- (42). Aranjuez GF, Kuhn HW, Adams PP, and Jewett MW (2019) *Borrelia burgdorferi* *bbk13* Is Critical for Spirochete Population Expansion in the Skin during Early Infection. *Infect. Immun* 87 (5), e00887–18. [PubMed: 30782856]

- (43). Caine JA, Lin YP, Kessler JR, Sato H, Leong JM, and Coburn J (2017) *Borrelia burgdorferi* outer surface protein C (OspC) binds complement component C4b and confers bloodstream survival. *Cell. Microbiol* 19, e12786.
- (44). Parveen N, Caimano M, Radolf JD, and Leong JM (2003) Adaptation of the Lyme disease spirochaete to the mammalian host environment results in enhanced glycosaminoglycan and host cell binding. *Mol. Microbiol* 47 (5), 1433–44. [PubMed: 12603746]
- (45). Fischer JR, LeBlanc KT, and Leong JM (2006) Fibronectin binding protein BBK32 of the Lyme disease spirochete promotes bacterial attachment to glycosaminoglycans. *Infection and immunity* 74 (1), 435–41. [PubMed: 16368999]
- (46). Benoit VM, Fischer JR, Lin YP, Parveen N, and Leong JM (2011) Allelic variation of the Lyme disease spirochete adhesin DbpA influences spirochetal binding to decorin, dermatan sulfate, and mammalian cells. *Infect. Immun* 79 (9), 3501–9. [PubMed: 21708995]
- (47). Lin YP, Chen Q, Ritchie JA, Dufour NP, Fischer JR, Coburn J, and Leong JM (2015) Glycosaminoglycan binding by *Borrelia burgdorferi* adhesin BBK32 specifically and uniquely promotes joint colonization. *Cell. Microbiol* 17 (6), 860–75. [PubMed: 25486989]
- (48). Lee WY, Moriarty TJ, Wong CH, Zhou H, Strieter RM, van Rooijen N, Chaconas G, and Kubes P (2010) An intravascular immune response to *Borrelia burgdorferi* involves Kupffer cells and iNKT cells. *Nat. Immunol* 11 (4), 295–302. [PubMed: 20228796]
- (49). Moriarty TJ, Shi M, Lin YP, Ebady R, Zhou H, Odisho T, Hardy PO, Salman-Dilgimen A, Wu J, Weening EH, Skare JT, Kubes P, Leong J, and Chaconas G (2012) Vascular binding of a pathogen under shear force through mechanistically distinct sequential interactions with host macromolecules. *Mol. Microbiol* 86 (5), 1116–31. [PubMed: 23095033]
- (50). Ebady R, Niddam AF, Boczula AE, Kim YR, Gupta N, Tang TT, Odisho T, Zhi H, Simmons CA, Skare JT, and Moriarty TJ (2016) Biomechanics of *Borrelia burgdorferi* Vascular Interactions. *Cell Rep.* 16 (10), 2593–604. [PubMed: 27568563]
- (51). Lin YP, Bhowmick R, Coburn J, and Leong JM (2015) Host cell heparan sulfate glycosaminoglycans are ligands for OspF-related proteins of the Lyme disease spirochete. *Cell. Microbiol* 17 (10), 1464–76. [PubMed: 25864455]
- (52). Fortune DE, Lin YP, Deka RK, Groshong AM, Moore BP, Hagman KE, Leong JM, Tomchick DR, and Blevins JS (2014) Identification of Lysine Residues in the *Borrelia burgdorferi* DbpA Adhesin Required for Murine Infection. *Infect. Immun* 82, 3186. [PubMed: 24842928]
- (53). Lin YP, Benoit V, Yang X, Martinez-Herranz R, Pal U, and Leong JM (2014) Strain-specific variation of the decorin-binding adhesin DbpA influences the tissue tropism of the Lyme disease spirochete. *PLoS Pathog.* 10 (7), e1004238. [PubMed: 25079227]
- (54). Guo BP, Brown EL, Dorward DW, Rosenberg LC, and Hook M (1998) Decorin-binding adhesins from *Borrelia burgdorferi*. *Mol. Microbiol* 30 (4), 711–23. [PubMed: 10094620]
- (55). Parveen N, and Leong JM (2000) Identification of a candidate glycosaminoglycan-binding adhesin of the Lyme disease spirochete *Borrelia burgdorferi*. *Mol. Microbiol* 35 (5), 1220–34. [PubMed: 10712702]
- (56). Yang X, Lin YP, Heselpoth RD, Buyuktanir O, Qin J, Rung F, Nelson DC, Leong JM, and Pal U (2016) Middle region of the *Borrelia burgdorferi* surface-located protein 1 (Lmp1) interacts with host chondroitin-6-sulfate and independently facilitates infection. *Cell. Microbiol* 18 (1), 97–110. [PubMed: 26247174]
- (57). Bolz DD, Sundsbak RS, Ma Y, Akira S, Kirschning CJ, Zachary JF, Weis JH, and Weis JJ (2004) MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. *J. Immunol* 173 (3), 2003–10. [PubMed: 15265935]
- (58). Liu N, Montgomery RR, Barthold SW, and Bockenstedt LK (2004) Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in *Borrelia burgdorferi*-infected mice. *Infection and immunity* 72 (6), 3195–203. [PubMed: 15155621]
- (59). Shin OS, Isberg RR, Akira S, Uematsu S, Behera AK, and Hu LT (2008) Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of *Borrelia burgdorferi* and cytokine induction. *Infection and immunity* 76 (6), 2341–51. [PubMed: 18378636]

- (60). Lawrenz MB, Wooten RM, Zachary JF, Drouin SM, Weis JJ, Wetsel RA, and Norris SJ (2003) Effect of complement component C3 deficiency on experimental Lyme borreliosis in mice. *Infection and immunity* 71 (8), 4432–40. [PubMed: 12874322]
- (61). Woodman ME, Cooley AE, Miller JC, Lazarus JJ, Tucker K, Bykowski T, Botto M, Hellwege J, Wooten RM, and Stevenson B (2007) *Borrelia burgdorferi* binding of host complement regulator factor H is not required for efficient mammalian infection. *Infection and immunity* 75 (6), 3131–9. [PubMed: 17420242]
- (62). Wang X, Ma Y, Weis JH, Zachary JF, Kirschning CJ, and Weis JJ (2005) Relative contributions of innate and acquired host responses to bacterial control and arthritis development in Lyme disease. *Infection and immunity* 73 (1), 657–60. [PubMed: 15618212]
- (63). Schaible UE, Kramer MD, Museteanu C, Zimmer G, Mossmann H, and Simon MM (1989) The severe combined immunodeficiency (scid) mouse. A laboratory model for the analysis of Lyme arthritis and carditis. *J. Exp. Med* 170 (4), 1427–32. [PubMed: 2794862]
- (64). McKisic MD, and Barthold SW (2000) T-cell-independent responses to *Borrelia burgdorferi* are critical for protective immunity and resolution of lyme disease. *Infection and immunity* 68 (9), 5190–7. [PubMed: 10948143]
- (65). Barthold SW, Sidman CL, and Smith AL (1992) Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. *Am. J. Trop. Med. Hyg* 47 (5), 605–13. [PubMed: 1449201]
- (66). Barthold SW, and Bockenstedt LK (1993) Passive immunizing activity of sera from mice infected with *Borrelia burgdorferi*. *Infect. Immun* 61 (11), 4696–702. [PubMed: 8406868]
- (67). Fikrig E, Bockenstedt LK, Barthold SW, Chen M, Tao H, Ali-Salaam P, Telford SR, and Flavell RA (1994) Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis. *J. Infect. Dis* 169 (3), 568–74. [PubMed: 8158028]
- (68). Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, Welch P, Marcus R, Aguero-Rosenfeld ME, Dennis DT, and Wormser GP (2001) Tick Bite Study, G., Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an *Ixodes scapularis* tick bite. *N. Engl. J. Med* 345 (2), 79–84. [PubMed: 11450675]
- (69). Wang Y, Kern A, Boatright NK, Schiller ZA, Sadowski A, Ejemel M, Souders CA, Reimann KA, Hu L, Thomas WD Jr., and Klempner MS (2016) Pre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes. *J. Infect. Dis* 214 (2), 205–11. [PubMed: 27338767]
- (70). Neves AR, Correia-da-Silva M, Sousa E, and Pinto M (2016) Strategies to Overcome Heparins' Low Oral Bioavailability. *Pharmaceuticals* 9 (3), 37.
- (71). Khatun Z, Nurunnabi, Cho KJ, Byun Y, Bae YH, and Lee YK (2014) Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. *J. Controlled Release* 177, 64–73.
- (72). Alam F, Al-Hilal TA, Chung SW, Seo D, Mahmud F, Kim HS, Kim SY, and Byun Y (2014) Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. *Biomaterials* 35 (24), 6543–52. [PubMed: 24816287]
- (73). Khatun Z, Nurunnabi M, Reeck GR, Cho KJ, and Lee YK (2013) Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. *J. Controlled Release* 170 (1), 74–82.
- (74). Berkowitz SD, Marder VJ, Kosutic G, and Baughman RA (2003) Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. *J. Thromb. Haemostasis* 1 (9), 1914–9. [PubMed: 12941031]
- (75). Kurtenbach K, Dizij A, Voet P, Hauser P, and Simon MM (1997) Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. *Vaccine* 15 (15), 1670–4. [PubMed: 9364698]
- (76). Ramana YV, Pandey AK, and Singh S (1992) Dimethoate toxicity to gestational embryonic ovary of a live bearing fish, *Lebistes reticulatus*. *Bull. Environ. Contam. Toxicol* 48 (6), 907–13. [PubMed: 1568069]

- (77). Bhattacharya D, Bensaci M, Luker KE, Luker G, Wisdom S, Telford SR, and Hu LT (2011) Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease. *Vaccine* 29 (44), 7818–25. [PubMed: 21816190]
- (78). Levin JD, Johnson AW, and Demple B (1988) Homogeneous Escherichia coli endonuclease IV. Characterization of an enzyme that recognizes oxidative damage in DNA. *J. Biol. Chem* 263 (17), 8066–8071. [PubMed: 2453510]
- (79). Marcinkiewicz AL, Lieknina I, Kotelovica S, Yang X, Kraiczy P, Pal U, Lin YP, and Tars K (2018) Eliminating Factor H-Binding Activity of *Borrelia burgdorferi* CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine. *Front. Immunol* 9, 181. [PubMed: 29472926]
- (80). Linhardt RJ, Rice KG, Kim YS, Lohse DL, Wang HM, and Loganathan D (1988) Mapping and quantification of the major oligosaccharide components of heparin. *Biochem. J* 254 (3), 781–7. [PubMed: 3196292]
- (81). Li L, Zhang F, Zaia J, and Linhardt RJ (2012) Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. *Anal. Chem* 84 (20), 8822–9. [PubMed: 22985071]
- (82). Li G, Steppich J, Wang Z, Sun Y, Xue C, Linhardt RJ, and Li L (2014) Bottom-up low molecular weight heparin analysis using liquid chromatography-Fourier transform mass spectrometry for extensive characterization. *Anal. Chem* 86 (13), 6626–32. [PubMed: 24905078]
- (83). Marcinkiewicz AL, Dupuis AP, 2nd, Zamba-Campero M, Nowak N, Kraiczy P, Ram S, Kramer LD, and Lin YP (2019) Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts. *Cell. Microbiol* 21 (2), e12998. [PubMed: 30571845]
- (84). Heroldova M, Nemeč M, and Hubalek Z (1998) Growth parameters of *Borrelia burgdorferi* sensu stricto at various temperatures. *Zentralbl. Bakteriol.* 288 (4), 451–5. [PubMed: 9987182]
- (85). Purser JE, and Norris SJ (2000) Correlation between plasmid content and infectivity in *Borrelia burgdorferi*. *Proc. Natl. Acad. Sci. U. S. A* 97 (25), 13865–70. [PubMed: 11106398]
- (86). Blevins JS, Hagman KE, and Norgard MV (2008) Assessment of decorin-binding protein A to the infectivity of *Borrelia burgdorferi* in the murine models of needle and tick infection. *BMC Microbiol.* 8, 82. [PubMed: 18507835]
- (87). Bunikis I, Kutschan-Bunikis S, Bonde M, and Bergstrom S (2011) Multiplex PCR as a tool for validating plasmid content of *Borrelia burgdorferi*. *J. Microbiol. Methods* 86 (2), 243–7. [PubMed: 21605603]
- (88). Hodzic E, Feng S, Freet KJ, and Barthold SW (2003) *Borrelia burgdorferi* population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. *Infection and immunity* 71 (9), 5042–55. [PubMed: 12933847]
- (89). Hart T, Yang X, Pal U, and Lin YP (2018) Identification of Lyme borreliae proteins promoting vertebrate host blood-specific spirochete survival in *Ixodes scapularis* nymphs using artificial feeding chambers. *Ticks and tick-borne diseases* 9, 1057. [PubMed: 29653905]




Figure 1. NACH bound to Lyme borreliae to prevent spirochete association with proteoglycans and GAGs. (A) Synthesis and structure of NACH: $m + n = 16$ for MW 12 kDa; $= H$ or HSO_3 ; $R_2 = Ac$ or HSO_3 . (B) The percentage of *B. burgdorferi* strains B314, B31-A3, or 297, *B. afzelii* strains CB43 or VS461-JL, or *B. garinii* strains ZQ1 or PBr that bind to NACH or to BSA as a negative control was determined by ELISA (see the Methods section). Each bar represents the mean of four independent determinations \pm standard deviation. Significant differences in spirochetal binding between indicated wells were determined using Mann–Whitney tests and are indicated (#, $P < 0.05$). (C–G) *B. burgdorferi* strains B314, B31-A3, or 297, *B. afzelii* strains CB43 or VS461-JL, or *B. garinii* strains ZQ1 or PBr were incubated with 2.5 mg mL⁻¹ NACH or BSA alone as a negative control for 1 h prior to being added to microtiter plate wells immobilized with (C) decorin, (D) biglycan, (E) heparan sulfate (HepSO₄), (F) dermatan sulfate (DermSO₄), or (G) BSA (negative control). Each bar represents the mean of four independent determinations \pm standard deviation. Significant reductions ($P < 0.05$) in spirochetal binding between different groups (#) or relative to BSA-treated spirochetes (*) are indicated using Mann–Whitney tests.




Figure 2.

NACH bound to Lyme borreliae to block the spirochetes' ability to attach to mammalian cells. *B. burgdorferi* strains B314 (negative control), B31-A3, or 297, *B. afzelii* strains CB43 or VS461-JL, or *B. garinii* strains ZQ1 or PBr were incubated with 2.5 mg mL⁻¹ NACH or PBS alone as a negative control (none) for 1 h prior to being added to microtiter plate wells containing (A) C6 glioma, (B) SVEC endothelial, or (C) SW982 synovial cells or BSA (negative control, data not shown). Each bar represents the mean of four independent determinations ± standard deviation. Significant reductions ($P < 0.05$) in spirochetal binding relative to the strain B314 (*) or to BSA-treated spirochetes (#) are indicated using Mann-Whitney tests.




Figure 3.

Spirochetes were eliminated at tick biting sites of skin in NACH-treated mice. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying *B. burgdorferi* strain B31. NACH (or PBS) was given daily in the same fashion until the mice were euthanized. At 7 days post-tick feeding (“dpf”), mice were euthanized. The spirochete burdens in the (A) biting site of the skin (“Inoc. Site”), (B) tibiotarsus joints (“tibiotarsus”), (C) heart, (D) ears, (E) knee joints (“knees”), and (F) bladder. Bacterial burdens were determined by qPCR and

normalized to 100 ng of total DNA. Uninfected, PBS-inoculated mice were included as the control (“-”). Shown are the geometric means \pm geometric standard deviations of five mice per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal–Wallis test with Dunn’s multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice (“*”) or between two treatment groups (“#”) are indicated.




Figure 4.

Spirochetes could not disseminate to distal tissues in NACH-treated mice. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying *B. burgdorferi* strain B31. NACH (or PBS) was given daily in the same fashion until the mice were euthanized. At 14 days post-tick feeding (“dpf”), mice were euthanized. The spirochete burdens in the (A) biting site of the skin (“Inoc. Site”), (B) tibiotarsus joints (“tibiotarsus”), (C) heart, (D) ears, (E) knee joints (“knees”), and (F) bladder. Ears were determined by qPCR and normalized to 100 ng of total

DNA. Uninfected, PBS-inoculated mice were included as the control (“-”). Shown are the geometric means \pm geometric standard deviations of five mice per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal–Wallis test with Dunn’s multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice (“**”) or between two treatment groups (“#”).




Figure 5.

Spirochetes were cleared from the bloodstream of the NACH-treated mice at an earlier onset than that of PBS-treated mice. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying the *B. burgdorferi* strain B31. NACH (or PBS) was given daily in the same fashion until the mice were euthanized. The spirochete burdens in the bloodstream were determined by qPCR and normalized to 100 ng of total DNA at (A) 4, (B) 7, (C) 10, or (D) 14 days post-tick feeding (“dpf”). Uninfected and PBS-inoculated mice were included as the control (“-”). Shown are the geometric means \pm geometric standard deviations of seven (for 7 dpf NACH-treated mice), ten (for 7 dpf, PBS-treated mice) or five mice (for the other time points) per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal–Wallis test with Dunn’s multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice (“*”) or between two treatment groups (“#”) are indicated.




Figure 6.

Mice administrated with NACH developed more robust antibodies against spirochetes than PBS-treated mice at the early stages of infection. Swiss-Webster mice were *intradermally* inoculated with NACH (5 mg per kg of mouse) or PBS at 24 h prior to being fed on by *I. scapularis* nymphs carrying the *B. burgdorferi* strain B31-A3. NACH (or PBS) was given daily in the same fashion until the mice were euthanized. The sera were obtained at (A and G) 4, (B and H) 7, (C and I) 10, (D and J) 14, (E and K) 21, and (F and L) 56 days post-tick feeding (“dpi”). Uninfected and PBS-inoculated mice were included as the control (“-”). The levels of IgG (A–F) and IgM (G–L) against the *B. burgdorferi* strain B31-A3 were determined using quantitative ELISA as described in the Methods section. Shown are the geometric means \pm geometric standard deviations of five mice per group in two experimental events. Significant differences ($P < 0.05$ by Kruskal–Wallis test with Dunn’s multiple comparison) in the spirochete burdens relative to uninfected and PBS-inoculated mice (“*”) or between two treatment groups (“#”) are indicated.

Table 1.

Serum Concentration of NACH in Mice 24 h after Inoculation

treatment	serum concentration of GAG (ng μL^{-1}) ^a		
	HepSO ₄ ^b	ChonSO ₄ ^c	hyaluronic acid
NACH	828.8 \pm 1.06 ^d	54417 \pm 1.19	561.6 \pm 1.18
PBS	712.1 \pm 1.03	51758 \pm 1.11	490.1 \pm 1.29

^aAll values represent the geometric mean \pm geometric standard deviation of seven (for NACH-treated mice) or five (for PBS-treated mice) mice per group.

^bHeparan sulfate.

^cChondroitin sulfate.

^dSignificantly greater value than heparan sulfate in the serum from PBS-treated mice using Mann–Whitney tests ($P=0.0051$).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript